Comment on: Feedback to Tolterodine QTMALHOTRA, B. K; GLUE, P.Clinical pharmacology and therapeutics. 2008, Vol 83, Num 2, pp 233-233, issn 0009-9236, 1 p.Article

LE SYNDROME ATROPINIQUE EN BREF = Anticholinergic syndrome brieflyLa Revue Prescrire. 2007, Vol 27, Num 290, pp 202-202, issn 0247-7750, 1 p., SUPArticle

Protection studies on anticholinesterase agents in ratsDAS GUPTA, S; BHATTACHARYA, R; PURNANAND et al.Pharmazie. 1990, Vol 45, Num 10, pp 801-802, issn 0031-7144, 2 p.Article

DISCRIMINABLE EFFECTS OF ANTIMUSCARINICS: DOSE RESPONSE AND SUBSTITUTION TEST STUDIES.OVERTON DA.1977; PHARMACOL. BIOCHEM. BEHAV.; U.S.A.; DA. 1977; VOL. 6; NO 6; PP. 659-666; BIBL. 19 REF.Article

Stratégie thérapeutique et impact des nouveaux traitementsHAAB, Francois.Annales d'urologie. 2005, Vol 39, pp S188-S191, issn 0003-4401, SUP6Conference Paper

Aclidinium bromide for the treatment of chronic obstructive pulmonary diseaseSTONE, Lowell E; SKELLEY, Jessica W; KYLE, Jeffrey A et al.American journal of health-system pharmacy. 2014, Vol 71, Num 5, pp 386-393, issn 1079-2082, 8 p.Article

Solifenacin Is Able to Improve the Irritative Symptoms After Transurethral Resection of Bladder TumorsZHENSHENG ZHANG; ZHI CAO; YINGHAO SUN et al.Urology (Ridgewood, NJ). 2014, Vol 84, Num 1, pp 117-121, issn 0090-4295, 5 p.Article

Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effectsHSIAO, Sheng-Mou; LIAO, Shih-Cheng; CHEN, Chi-Hau et al.Maturitas (Amsterdam). 2014, Vol 79, Num 4, pp 428-434, issn 0378-5122, 7 p.Article

Aclidinium Bromide Twice Daily for the Treatment of Chronic Obstructive Pulmonary Disease: A ReviewJONES, Paul.Advances in therapy. 2013, Vol 30, Num 4, pp 354-368, issn 0741-238X, 15 p.Article

Evaluation of tropicamide-loaded tamarind seed xyloglucan nanoaggregates for ophthalmic deliveryDILBAGHI, Neeraj; KAUR, Harmanmeet; AHUJA, Munish et al.Carbohydrate polymers. 2013, Vol 94, Num 1, pp 286-291, issn 0144-8617, 6 p.Article

Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladderLESHENG TENG; CHAOJUN JIANG; FENGYING SUN et al.Journal of microencapsulation. 2013, Vol 30, Num 2, pp 116-123, issn 0265-2048, 8 p.Article

Tolterodine for the treatment of urge urinary incontinenceELTERMAN, Dean S; CHUGHTAI, Bilal; KAPLAN, Steven A et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 14, pp 1987-1991, issn 1465-6566, 5 p.Article

New developments in the medical management of overactive bladderROBINSON, Dudley; GIARENIS, Ilias; CARDOZO, Linda et al.Maturitas (Amsterdam). 2013, Vol 76, Num 3, pp 225-229, issn 0378-5122, 5 p.Article

Comparative adherence to oxybutynin or tolterodine among older patientsGOMES, Tara; JUURLINK, David N; MAMDANI, Muhammad M et al.European journal of clinical pharmacology. 2012, Vol 68, Num 1, pp 97-99, issn 0031-6970, 3 p.Article

Intoxication with a tropenol esterMUTTRAY, A; SCHNEIDER, M; LETZEL, S et al.Occupational medicine (Oxford). 2012, Vol 62, Num 4, pp 305-307, issn 0962-7480, 3 p.Article

Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic reviewKAPLAN, S. A; ROEHRBORN, C. G; ABRAMS, P et al.International journal of clinical practice (Esher). 2011, Vol 65, Num 4, pp 487-507, issn 1368-5031, 21 p.Article

Nocturia: A Nonspecific but Bothersome Symptom in UrologyCHEN, Sung-Lang.Urological science. 2011, Vol 22, Num 1, pp 1-6, 6 p.Article

Systematic Review and Meta-Analysis: Do Clinical Trials Testing Antimuscarinic Agents for Overactive Bladder Adequately Measure Central Nervous System Adverse EventsPAQUETTE, Amélie; GOU, Pauline; TANNENBAUM, Cara et al.Journal of the American Geriatrics Society. 2011, Vol 59, Num 7, pp 1332-1339, issn 0002-8614, 8 p.Article

New once-daily formulation for trospium in overactive bladderCHAPPLE, C.International journal of clinical practice (Esher). 2010, Vol 64, Num 11, pp 1535-1540, issn 1368-5031, 6 p.Article

Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended releaseSTASKIN, D. R; CARDOZO, L.International journal of clinical practice (Esher). 2009, Vol 63, Num 6, pp 973-976, issn 1368-5031, 4 p.Article

Safety and Tolerability of Solifenacin Add-on Therapy to α-Blocker Treated Men With Residual Urgency and FrequencyKAPLAN, Steven A; MCCAMMON, Kurt; FINCHER, Roger et al.The Journal of urology. 2009, Vol 182, Num 6, pp 2825-2830, issn 0022-5347, 6 p., 1Article

Tolterodine Extended Release With or Without Tamsulosin in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms : Effects of Prostate Size. CommentariesROEHRBORN, Claus G; KAPLAN, Steuen A; JONES, J. Stephen et al.European urology. 2009, Vol 55, Num 2, pp 472-481, issn 0302-2838, 10 p.Article

Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With α-BlockersCHAPPLE, Christopher; HERSCHORN, Sender; ABRAMS, Paul et al.European urology. 2009, Vol 56, Num 3, pp 534-543, issn 0302-2838, 10 p.Article

Transdermal OxybutyninBALDWIN, Claudine M; KEATING, Gillian M.Drugs (Basel). 2009, Vol 69, Num 3, pp 327-337, issn 0012-6667, 11 p.Article

Treatment With Solifenacin Increases Warning Time and Improves Symptoms of Overactive Bladder : Results From VENUS, a Randomized, Double-Blind, Placebo-Controlled TrialKARRAM, Mickey M; TOGLIA, Marc R; SERELS, Scott R et al.Urology (Ridgewood, NJ). 2009, Vol 73, Num 1, pp 14-18, issn 0090-4295, 5 p.Article